GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Clinical trial enrollment has long been a bottleneck in drug development
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The FDA aims to make a decision by April 8, 2026
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
